Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer ; volume:91 ; number:3 ; day:9 ; month:3 ; year:2023 ; pages:247-256 ; date:3.2023
Cancer chemotherapy and pharmacology ; 91, Heft 3 (9.3.2023), 247-256, 3.2023
- Creator
-
Jong, Loek A. W. de
Lambert, Marie
Erp, Nielka P. van
Vries, Lukas de
Chatelut, Etienne
Ottevanger, Petronella B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-023-04512-z
- URN
-
urn:nbn:de:101:1-2023081110353551738413
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jong, Loek A. W. de
- Lambert, Marie
- Erp, Nielka P. van
- Vries, Lukas de
- Chatelut, Etienne
- Ottevanger, Petronella B.
- SpringerLink (Online service)
Other Objects (12)
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Intraperitoneal therapy for ovarian cancer
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Intraperitoneal therapy for ovarian cancer
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells